Classifying mental disorders using traditional tools like the Diagnostic and Statistical Manual misses the vast differences in biomarkers that can exist in patients with the same diagnosis, which is why research is looking to biological measures and “biotypes” to provide more information, according to Godfrey Pearlson, MD, professor of psychiatry and neuroscience, Yale School of Medicine.
Classifying mental disorders using traditional tools like the Diagnostic and Statistical Manual (DSM) misses the vast differences in biomarkers that can exist in patients with the same diagnosis, which is why research is looking to biological measures and “biotypes” to provide more information, according to Godfrey Pearlson, MD, professor of psychiatry and neuroscience, Yale School of Medicine.
Transcript
How could biologic measures be used to create a new framework of psychiatric diseases?
So, if you just temporarily toss out conventional DSM-type traditional psychiatric measures and start from the bottom up, using only biology as a classifier, you end up with very, very different syndromes. For example in the B-SNIP project, looking at bipolar illness, schizoaffective disorder, and schizophrenia, when we took that approach to just removing DSM labels from patients with psychotic illnesses, putting them all into one huge group, trying to classify them from the bottom up using biology, we came up with 3 new typologies that we call biotypes.
Each biotype contains people with each of the 3 diagnoses, and they all look very similar symptomatically—they all have hallucinations and delusions and some mood symptoms—but from the point of view of biology they look completely different from each other, even in opposite directions. So some biological measure may be greatly increased above normal in one group, in one biotype, and way below normal in the other, but they, say, may be both containing people with schizophrenia, so you can imagine what would happen if you averaged across people who are way high and way low, you’d just be very confused, which is I think the way biology is at the moment.
So I think if you classify based on biology, which is sort of what RDoC [Research Domain Criteria] from NIMH is trying to do, you end up ahead on average, and more informed, with more facts than you had before.
Which biological measures hold the most promise as indicators for classifying these illnesses and why?
Yeah, well that’s the key question. We really don’t know the answer to that yet. We have a lot of measures, and most likely, I think, in the beginning, we’ll find fingerprints that identify new diseases, classified by biology, that are based on an agglomeration, a mixture of different kinds of biological indicators. I don’t think there’s any one that’s going to be key in the beginning, but it’ll be a mixture that leads to a fingerprint.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More